VIEWPOINTS


Viewpoints are a collection of news and opinion articles that capture key research developments and important issues in the field of oncology.


Breast Cancer: Determining the Best Diet for Disease Prevention

Breast Cancer: Determining the Best Diet for Disease Prevention

Higher ERDP scores were significantly associated with developing breast cancer.

Widening the Use of Preventive Therapies Against Breast Cancer

Widening the Use of Preventive Therapies Against Breast Cancer

Preventive treatments are strongly recommended in women with AH and LCIS.

Late-Onset Toxicity Possible With Immunotherapy

Late-Onset Toxicity Possible With Immunotherapy

Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.

Diet and Dosage: How Much Could Patients Save?

Diet and Dosage: How Much Could Patients Save?

Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.

Brentuximab in Classical Hodgkin Lymphoma — In the Clinic

Brentuximab in Classical Hodgkin Lymphoma — In the Clinic

Brentuximab vedotin is an anti-CD30 monoclonal antibody that targets the Reed-Sternberg cells found in patients with classical HL.

Identifying the Optimal Breast Cancer Screening Interval

Identifying the Optimal Breast Cancer Screening Interval

It is unclear whether breast cancer screening — and specifically mammography — reduces the likelihood of being diagnosed with advanced-stage disease.

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.

In Focus: Voxtalisib for CLL and B-Cell Lymphomas

In Focus: Voxtalisib for CLL and B-Cell Lymphomas

Voxtalisib is a potent inhibitor of 4 PI3K isoforms (p110α, p110β, p110γ, and p110δ) and a weaker inhibitor of mTOR.

Obstructing Colorectal Cancer: Presentation and Stenting — In the Clinic

Obstructing Colorectal Cancer: Presentation and Stenting — In the Clinic

Colonic stenting can be used as a temporizing measure to help bridge the patient to surgery for optimal timing.

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic

Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic

Patients who undergo this cosmetic procedure should be counseled on the increased risk of BIA ALCL.

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.

Curbing Regulatory Capture: A Q&A With Bishal Gyawali, MD, PhD

Curbing Regulatory Capture: A Q&A With Bishal Gyawali, MD, PhD

Cancer Therapy Advisor asked Dr Gyawali, who coauthored a viewpoint just published in JAMA Oncology, to discuss the FDA's approval of sunitinib, and whether it is an example of what he calls "regulatory capture" in medicine.

Clofarabine: An Unclear Role in Lymphoma Care

Clofarabine: An Unclear Role in Lymphoma Care

To date, studies of clofarabine in patients with lymphoma have been limited by small patient numbers and myelosuppression toxicities.

VHL and the Risk for Renal Cell Carcinoma — In the Clinic

VHL and the Risk for Renal Cell Carcinoma — In the Clinic

Close to 60% of all patients with VHL will develop RCC or renal cysts.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs